Glenmark Expands Oncology Portfolio With Aumolertinib Deal

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals, has signed an exclusive licensing and distribution agreement with Jiangsu Hansoh Pharmaceutical Group.

The agreement is for Aumolertinib, a third-generation EGFR-TKI for the treatment of non-small cell lung cancer (NSCLC). The deal strengthens Glenmark’s oncology presence across international markets.

Under the agreement, Glenmark has secured development and commercialization rights for Aumolertinib across the Middle East, Africa, Southeast and South Asia, Australia, New Zealand, and Russia/CIS.

Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future

In return, Hansoh Pharma will receive an upfront payment in the low double-digit millions, along with additional development, regulatory, and sales-based milestone payments. Total milestone and royalty payments could eventually exceed $1 billion.

“At Glenmark, we remain focused on building a growth-oriented oncology business across high-potential markets. Aumolertinib is a strategic addition that strengthens our near-term commercial pipeline and enhances our ability to serve patients with EGFR-mutated lung cancer. This collaboration reinforces our disciplined approach to expanding our innovative portfolio and widening access to advanced cancer care across key markets,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd.

Aumolertinib, marketed as Ameile in China and Aumseqa in the United Kingdom and Europe, has received marketing authorization from the UK MHRA. It is approved as a monotherapy for first-line treatment of adults with locally advanced or metastatic NSCLC with activating EGFR mutations, and for patients with EGFR T790M mutation-positive disease.

In China, the drug is approved across four indications, including first-line EGFR-mutated NSCLC, second-line T790M mutation, unresectable Stage III disease following chemoradiotherapy, and adjuvant Stage II–IIIB NSCLC. It became Hansoh Pharma’s first innovative therapy approved outside China and the first China-developed EGFR-TKI launched internationally.